Drugs / Sofosbuvir/Velpatasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05016609 | Mar 2022 → Apr 2024 | hepatitis C virus infection | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sofosbuvir/Velpatasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05016609 ↗ |